HMC in Qatar introduces Lutetium-177 nuclear medicine treatment for prostate cancer patients, offering a local alternative.

Hamad Medical Corporation (HMC) in Qatar introduces Lutetium-177 nuclear medicine treatment for the first time, offering prostate cancer patients a local alternative to travelling abroad for treatment. The technology can also diagnose breast cancer tumours and improve quality of life for patients with neuroendocrine tumours and prostate cancer. HMC aims to incorporate advanced treatment modalities to reduce patients' need to seek medical care abroad.

April 28, 2024
4 Articles